Mahajan A, Brunson A, Adesina O, Keegan THM, Wun T. The incidence of cancer-associated thrombosis is increasing over time. Blood Adv. 2022;6(1):307–20.

Article  PubMed  PubMed Central  Google Scholar 

Falanga A, Russo L, Milesi V, Vignoli A. Mechanisms and risk factors of thrombosis in cancer. Crit Rev Oncol-Hematol. 2017;118:79–83.

Article  PubMed  Google Scholar 

Lewis-Lloyd CA, Pettitt EM, Adiamah A, Crooks CJ, Humes DJ. Risk of postoperative venous thromboembolism after surgery for colorectal malignancy: a systematic review and meta-analysis. Dis Colon Rectum. 2021;64(4):484–96.

Article  PubMed  Google Scholar 

Theochari NA, Theochari CA, Kokkinidis DG, Kechagias A, Lyros O, Giannopoulos S, et al. Venous thromboembolism after esophagectomy for cancer: a systematic review of the literature to evaluate incidence, risk factors, and prophylaxis. Surg Today. 2022. https://doi.org/10.1007/s00595-021-02260-2.

Article  PubMed  Google Scholar 

Chiasakul T, Patell R, Maraveyas A, Carrier M, Zwicker JI. Discordant reporting of VTE in pancreatic cancer: a systematic review and meta-analysis of thromboprophylaxis versus chemotherapeutic trials. J Thromb Haemost. 2021;19(2):489–501.

Article  PubMed  Google Scholar 

Recio-Boiles A, Veeravelli S, Vondrak J, Babiker HM, Scott AJ, Shroff RT, et al. Evaluation of the safety and effectiveness of direct oral anticoagulants and low molecular weight heparin in gastrointestinal cancer-associated venous thromboembolism. World J Gastrointest Oncol. 2019;11(10):866–76.

Article  PubMed  PubMed Central  Google Scholar 

Ageno W, Vedovati MC, Cohen A, Huisman M, Bauersachs R, Gussoni G, et al. Bleeding with Apixaban and Dalteparin in patients with Cancer-Associated venous thromboembolism: results from the Caravaggio study. Thromb Haemost. 2021;121(5):616–24.

Article  PubMed  Google Scholar 

Alikhan R, Gomez K, Maraveyas A, Noble S, Young A, Thomas M. Cancer-associated venous thrombosis in adults (second edition): a British society for haematology guideline. Br J Haematol. 2024;205(1):71–87.

Article  PubMed  Google Scholar 

Mokadem ME, Hassan A, Algaby AZ. Efficacy and safety of Apixaban in patients with active malignancy and acute deep venous thrombosis. Vascular. 2021;29(5):745–50.

Article  CAS  PubMed  Google Scholar 

Mulder FI, van Es N, Kraaijpoel N, Di Nisio M, Carrier M, Duggal A, et al. Edoxaban for treatment of venous thromboembolism in patient groups with different types of cancer: results from the Hokusai VTE cancer study. Thromb Res. 2020;185:13–9.

Article  CAS  PubMed  Google Scholar 

Kim JH, Yoo C, Seo S, Jeong JH, Ryoo BY, Kim KP, et al. A phase II study to compare the safety and efficacy of direct oral anticoagulants versus subcutaneous Dalteparin for cancer-associated venous thromboembolism in patients with advanced upper gastrointestinal, hepatobiliary and pancreatic cancer: PRIORITY. Cancers (Basel). 2022. https://doi.org/10.3390/cancers14030559.

Article  PubMed  PubMed Central  Google Scholar 

Chen DY, Tseng CN, Hsieh MJ, Lan WC, Chuang CK, Pang ST, et al. Comparison between non-vitamin K antagonist oral anticoagulants and low-molecular-weight heparin in Asian individuals with cancer-associated venous thromboembolism. JAMA Netw Open. 2021;4(2):e2036304.

Article  PubMed  PubMed Central  Google Scholar 

Rungjirajittranon T, Owattanapanich W, Chinthammitr Y, Ruchutrakool T, Suwanawiboon B. Direct oral anticoagulants versus low-molecular-weight heparins for the treatment of acute venous thromboembolism in patients with Gastrointestinal cancer: a systematic review and meta-analysis. Thromb J. 2022;20(1):41.

Article  PubMed  PubMed Central  Google Scholar 

Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71.

Article  PubMed  PubMed Central  Google Scholar 

Sterne JAC, Savović J, Page MJ, Elbers RG, Blencowe NS, Boutron I, Cates CJ, Cheng HY, Corbett MS, Eldridge SM, Emberson JR, Hernán MA, Hopewell S, Hróbjartsson A, Junqueira DR, Jüni P, Kirkham JJ, Lasserson T, Li T, McAleenan A, Reeves BC, Shepperd S, Shrier I, Stewart LA, Tilling K, White IR, Whiting PF, Higgins JPT. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366:l4898. https://doi.org/10.1136/bmj.l4898. PMID: 31462531.

Caroti KS, Khorana AA, Becattini C, Lee AYY, Ekbom A, Carrier M, et al. Rivaroxaban versus low-molecular-weight heparins in a broad cohort of patients with cancer-associated venous thromboembolism: an analysis of the OSCAR-US program. Clinical and Applied Thrombosis/Hemostasis. 2023;29:10760296231189282.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Cohen AT, Keshishian A, Lee T, Rosenblatt L, Hlavacek P, Sah J, et al. Effectiveness and safety of apixaban, LMWH, and warfarin among high-risk subgroups of VTE patients with active cancer. Curr Med Res Opin. 2021;37(9):1467–82.

Article  CAS  PubMed  Google Scholar 

Guan T, Laguna A, Soares A, Legasto CS, Block S, Saunders IM, et al. Evaluation of direct oral anticoagulants versus low molecular weight heparins for venous thromboembolism treatment in patients with gastrointestinal malignancies. J Thromb Thrombolysis. 2023;56(3):439–46.

Article  CAS  PubMed  Google Scholar 

Houghton DE, Vlazny DT, Casanegra AI, Brunton N, Froehling DA, Meverden RA, et al. Bleeding in patients with gastrointestinal cancer compared with nongastrointestinal cancer treated with apixaban, rivaroxaban, or enoxaparin for acute venous thromboembolism. Mayo Clin Proc. 2021;96(11):2793–805.

Article  CAS  PubMed  Google Scholar 

Lee JH, Oh YM, Lee SD, Lee JS. Rivaroxaban versus low-molecular-weight heparin for venous thromboembolism in gastrointestinal and pancreatobiliary cancer. J Korean Med Sci. 2019;34(21):e160.

Article  PubMed  PubMed Central  Google Scholar 

Kim JH, Seo S, Kim KP, Chang HM, Ryoo BY, Yoo C, et al. Rivaroxaban versus low-molecular-weight heparin for venous thromboembolism in advanced upper gastrointestinal tract and hepatopancreatobiliary cancer. In Vivo. 2020;34(2):829–37.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Agnelli G, Muñoz A, Franco L, Mahé I, Brenner B, Connors JM, et al. Apixaban and Dalteparin for the treatment of venous thromboembolism in patients with different sites of cancer. Thromb Haemost. 2022;122(5):796–807.

Article  PubMed  Google Scholar 

Young AM, Marshall A, Thirlwall J, Chapman O, Lokare A, Hill C, et al. Comparison of an oral factor Xa inhibitor with low molecular weight heparin in patients with cancer with venous thromboembolism: results of a randomized trial (SELECT-D). J Clin Oncol. 2018;36(20):2017–23.

Article  CAS  PubMed  Google Scholar 

Safieddine M, Chapelle C, Ollier E, Ferdynus C, Bertoletti L, Mismetti P, et al. Compared to randomized studies, observational studies may overestimate the effectiveness of doacs: a metaepidemiological approach. J Clin Epidemiol. 2021;130:49–58.

Article  PubMed  Google Scholar 

Zhou H, Chen TT, Ye LL, Ma JJ, Zhang JH. Efficacy and safety of direct oral anticoagulants versus low-molecular-weight heparin for thromboprophylaxis after cancer surgery: a systematic review and meta-analysis. World J Surg Oncol. 2024;22(1):69.

Article  PubMed  PubMed Central  Google Scholar 

Mousavi A, Shojaei S, Rahmati S, Dastjerdi P, Sabri M, Salehi K, et al. Direct oral anticoagulants versus low-molecular-weight heparin in patients with cancer-associated thrombosis: a meta-analysis of randomized controlled trials. Am J Cardiol. 2025;254:32–41.

Article  CAS  PubMed  Google Scholar 

Zhou H, Ye LL, Zhou JT, Ma FX, Ma JJ, Zhang JH. Direct oral anticoagulants (DOACs) versus low-molecular-weight heparin (LMWH) for extended thromboprophylaxis following major abdominal/pelvic cancer-related surgery: a systematic review and meta-analysis. Surg Endosc. 2024;38(3):1131–8.

Article  PubMed  Google Scholar 

Lee MC, Wu JY, Yu T, Liao CT, Chang WT, Toh HS et al. Clinical Efficacy and Safety of Novel Anticoagulants for the Management of Venous Thromboembolism in Patients with Cancer: A Systematic Review and Meta-Analysis. Cardiovascular drugs and therapy. 2024.

Song X, Liu Z, Zeng R, Shao J, Liu B, Zheng Y, et al. Treatment of venous thromboembolism in cancer patients: a systematic review and meta-analysis on the efficacy and safety of different direct oral anticoagulants (DOACs). Ann Transl Med. 2021;9(2):162.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wumaier K, Li W, Chen N, Cui J. Direct oral anticoagulants versus low molecular weight heparins for the treatment of cancer-associated thrombosis: a cost-effectiveness analysis. Thromb J. 2021;19(1):68.

Article  CAS  PubMed  PubMed Central  Google Scholar